Worth reading
69In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Decision and Details
European Patent OfficeIntention to Grant (Rule 71(3)) for a European patent covering the blood cancer treatment use of the CDC7 inhibitor monzosertib
Decision5 October 2025 (date notification received)
ImplementationThe patent is expected to be registered following the requisite procedures (scheduled registration date unknown).
Going forwardThe patent is expected to be registered in Europe following the requisite procedures.
Quantity / scaleEuropean patent application No. 19866944.2; covers blood cancer treatment uses, including AML
Reason
Following examination by the European Patent Office, the invention was determined to merit the grant of patent rights.
| Item | Details |
|---|---|
| Matter Covered | Intention to Grant (Rule 71(3)) for a European patent covering the blood cancer treatment use of the CDC7 inhibitor monzosertib |
| Decision-Making Body | European Patent Office |
| Decision Date | 5 October 2025 (date notification received) |
| Implementation Date | The patent is expected to be registered following the requisite procedures (scheduled registration date unknown). |
| Quantity / scale | European patent application No. 19866944.2; covers blood cancer treatment uses, including AML |
| Reason | Following examination by the European Patent Office, the invention was determined to merit the grant of patent rights. |
| Governing Rule | Rule 71(3) |
| Future plans | The patent is expected to be registered in Europe following the requisite procedures. |
Items this document does not state (4)
Period CoveredAmountImpact on Business PerformanceRelated previous disclosures
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following examination by the European Patent Office, the invention was determined to merit the grant of patent rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.